Work

Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw383.08

Authors: L. Bazhenova, S. Gettinger, C. Langer, R. Salgia, K. Gold, R. Rosell, A. Shaw, G. Weiss, J. Haney, V. Rivera, F. Haluska, D. Kerstein, D.R. Camidge

Institutions: University of California San Diego, Moores Cancer Center, Yale Cancer Center, Abramson Cancer Center, University of Pennsylvania, City Of Hope National Medical Center, City of Hope, Institut Català d'Oncologia, Massachusetts General Hospital, Western Regional Medical Center, ARIAD Pharmaceuticals (United States), University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2586866733

FWCI: 0.895

Cites:

Cited by: 3

Related to: 10